Lundbeck Showcases Promising Phase II Results for Asedebart in Cushing's Disease at ENDO 2026

Lundbeck's New Phase II Data on Asedebart for Cushing's Disease

In an exciting development for the treatment of Cushing's disease (CD), H. Lundbeck A/S revealed promising preliminary results from their Phase II Part A study on asedebart (Lu AG13909) at the 2026 Endocrine Society's Annual Meeting (ENDO) in Chicago. Cushing's disease is a rare endocrine disorder caused by excessive adrenocorticotropic hormone (ACTH) production, often due to a pituitary adenoma, leading to an overproduction of cortisol, which can significantly affect a patient's quality of life and overall health.

Asedebart is a humanized monoclonal antibody developed to target and neutralize excessive levels of ACTH, thereby reducing cortisol production. Cortisol overproduction is a defining characteristic of Cushing's disease, making the ability to normalize urinary free cortisol (UFC) levels a key focus for researchers. The Phase II study aimed to evaluate the safety and efficacy of asedebart through individualized intravenous (IV) dose titration.

Positive Preliminary Findings

During the presentation on June 14, 2026, Lundbeck's researchers shared that 7 out of 8 evaluable patients in the IV dosing group had achieved UFC normalization, a critical marker of treatment success in CD. This is particularly noteworthy as normalization of UFC is strongly correlated with decreased morbidity and improved quality of life for patients.

Johan Luthman, EVP and Head of Research Development at Lundbeck, emphasized the importance of these findings. “The data from the ongoing Phase II study highlight the potential of direct ACTH neutralization as a novel therapeutic approach in Cushing's disease, where significant unmet medical needs still exist,” he stated. The absence of serious safety concerns, alongside the encouraging efficacy data, strengthens the rationale for progressing asedebart into subsequent phases of clinical evaluation.

Safety and Tolerability

While the results were promising, it is crucial to consider the safety profile observed during the study. Although treatment-emergent adverse events were reported among the participants, no unexpected adverse reactions were documented. Serious adverse events occurred in three patients, one of which resulted in death from an unrelated cause. Notably, there were no cases of hypersensitivity reported. Some participants did exhibit glucocorticoid deficiency, which was managed effectively with short-term hydrocortisone treatment, also reflecting the meticulous approach taken by Lundbeck in monitoring patient responses.

Next Steps

Following the Phase II Part A results, Part B of the study is underway. It seeks to explore the subcutaneous administration of asedebart, assessing both safety and pharmacokinetics alongside patient experience with this delivery method. This next phase is critical for determining how best to provide effective and convenient treatment options for patients suffering from Cushing's disease.

The Bigger Picture

The significance of asedebart extends beyond its mechanism of ACTH neutralization; it is a representation of Lundbeck's commitment to advancing treatment options for rare endocrine disorders. With over 70 years of expertise in neuroscience, Lundbeck is determined to leverage its knowledge to develop innovative solutions that meet the diverse needs of patients with complex conditions. Asedebart has already been given Orphan Drug Designation in both the European Union and Japan for its application in Cushing's disease and congenital adrenal hyperplasia, indicating the drug's potential to address significant health challenges.

Conclusion

Lundbeck's presentation at ENDO 2026 reinforces the company's dedication to addressing pressing health issues through groundbreaking research. As the ongoing study progresses, the medical community and patients alike will be watching closely to see how asedebart might significantly benefit individuals challenged by Cushing's disease. The preliminary results provide hope for a future where effective, well-tolerated therapies can improve the lives of many affected by this challenging condition.

For more information about Lundbeck and their ongoing research, visit their official website at www.lundbeck.com.